• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用 Simcyp 模拟器的参数和非参数方法以及贝叶斯采样器进行群体 PBPK 建模。

Population PBPK modeling using parametric and nonparametric methods of the Simcyp Simulator, and Bayesian samplers.

机构信息

CERTARA UK Limited, Simcyp Division, Sheffield, UK.

出版信息

CPT Pharmacometrics Syst Pharmacol. 2022 Jun;11(6):755-765. doi: 10.1002/psp4.12787. Epub 2022 Apr 22.

DOI:10.1002/psp4.12787
PMID:35385609
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9197540/
Abstract

Physiologically-based pharmacokinetic (PBPK) models usually include a large number of parameters whose values are obtained using in vitro to in vivo extrapolation. However, such extrapolations can be uncertain and may benefit from inclusion of evidence from clinical observations via parametric inference. When clinical interindividual variability is high, or the data sparse, it is essential to use a population pharmacokinetics inferential framework to estimate unknown or uncertain parameters. Several approaches are available for that purpose, but their relative advantages for PBPK modeling are unclear. We compare the results obtained using a minimal PBPK model of a canonical theophylline dataset with quasi-random parametric expectation maximization (QRPEM), nonparametric adaptive grid estimation (NPAG), Bayesian Metropolis-Hastings (MH), and Hamiltonian Markov Chain Monte Carlo sampling. QRPEM and NPAG gave consistent population and individual parameter estimates, mostly agreeing with Bayesian estimates. MH simulations ran faster than the others methods, which together had similar performance.

摘要

生理药代动力学(PBPK)模型通常包含大量参数,这些参数的值是通过体外到体内外推获得的。然而,这种外推可能存在不确定性,并且可以通过参数推断纳入临床观察证据来获益。当个体间变异性高或数据稀疏时,使用群体药代动力学推断框架来估计未知或不确定的参数至关重要。为此目的有几种方法,但它们在 PBPK 建模方面的相对优势尚不清楚。我们比较了使用最小 PBPK 模型对典型茶碱数据集进行模拟的结果,以及准随机参数期望最大化(QRPEM)、非参数自适应网格估计(NPAG)、贝叶斯马尔可夫链蒙特卡罗采样(MH)。QRPEM 和 NPAG 给出了一致的群体和个体参数估计值,与贝叶斯估计值大多一致。MH 模拟比其他方法运行得更快,而其他方法的性能相似。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bcb/9197540/df7d696abe6e/PSP4-11-755-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bcb/9197540/f9191b9c43b1/PSP4-11-755-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bcb/9197540/7346c2ac65b9/PSP4-11-755-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bcb/9197540/c5f947d4df18/PSP4-11-755-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bcb/9197540/0fd33e3379c8/PSP4-11-755-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bcb/9197540/8ca18152c50f/PSP4-11-755-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bcb/9197540/df7d696abe6e/PSP4-11-755-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bcb/9197540/f9191b9c43b1/PSP4-11-755-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bcb/9197540/7346c2ac65b9/PSP4-11-755-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bcb/9197540/c5f947d4df18/PSP4-11-755-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bcb/9197540/0fd33e3379c8/PSP4-11-755-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bcb/9197540/8ca18152c50f/PSP4-11-755-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bcb/9197540/df7d696abe6e/PSP4-11-755-g002.jpg

相似文献

1
Population PBPK modeling using parametric and nonparametric methods of the Simcyp Simulator, and Bayesian samplers.使用 Simcyp 模拟器的参数和非参数方法以及贝叶斯采样器进行群体 PBPK 建模。
CPT Pharmacometrics Syst Pharmacol. 2022 Jun;11(6):755-765. doi: 10.1002/psp4.12787. Epub 2022 Apr 22.
2
Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.参数和非参数总体方法:它们在分析临床数据集和两项蒙特卡罗模拟研究中的比较性能。
Clin Pharmacokinet. 2006;45(4):365-83. doi: 10.2165/00003088-200645040-00003.
3
Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations.基于贝叶斯群体生理药代动力学(PBPK)方法对临床相关群体个体间变异性进行生理现实特征描述
PLoS One. 2015 Oct 2;10(10):e0139423. doi: 10.1371/journal.pone.0139423. eCollection 2015.
4
Well-tempered MCMC simulations for population pharmacokinetic models.经过良好调整的群体药代动力学模型的 MCMC 模拟。
J Pharmacokinet Pharmacodyn. 2020 Dec;47(6):543-559. doi: 10.1007/s10928-020-09705-0. Epub 2020 Jul 31.
5
Reduction of a Whole-Body Physiologically Based Pharmacokinetic Model to Stabilise the Bayesian Analysis of Clinical Data.简化基于生理的全身药代动力学模型以稳定临床数据的贝叶斯分析
AAPS J. 2016 Jan;18(1):196-209. doi: 10.1208/s12248-015-9840-7. Epub 2015 Nov 4.
6
Lifetime PCB 153 bioaccumulation and pharmacokinetics in pilot whales: Bayesian population PBPK modeling and Markov chain Monte Carlo simulations.领航鲸体内多氯联苯153的终生生物累积和药代动力学:贝叶斯群体生理药代动力学建模与马尔可夫链蒙特卡洛模拟
Chemosphere. 2014 Jan;94:91-6. doi: 10.1016/j.chemosphere.2013.09.019. Epub 2013 Sep 27.
7
Performance comparison of first-order conditional estimation with interaction and Bayesian estimation methods for estimating the population parameters and its distribution from data sets with a low number of subjects.从样本量较小的数据集估计总体参数及其分布的一阶条件估计与交互和贝叶斯估计方法的性能比较。
BMC Med Res Methodol. 2017 Dec 1;17(1):154. doi: 10.1186/s12874-017-0427-0.
8
Revised assessment of cancer risk to dichloromethane: part I Bayesian PBPK and dose-response modeling in mice.二氯甲烷癌症风险的修订评估:第一部分 小鼠中的贝叶斯PBPK和剂量反应模型
Regul Toxicol Pharmacol. 2006 Jun;45(1):44-54. doi: 10.1016/j.yrtph.2005.12.007. Epub 2006 Jan 25.
9
Application of Bayesian population physiologically based pharmacokinetic (PBPK) modeling and Markov chain Monte Carlo simulations to pesticide kinetics studies in protected marine mammals: DDT, DDE, and DDD in harbor porpoises.贝叶斯群体生理药代动力学(PBPK)建模和马尔可夫链蒙特卡罗模拟在保护海洋哺乳动物中农药动力学研究中的应用:DDT、DDE 和 DDD 在港豚中的研究。
Environ Sci Technol. 2013 May 7;47(9):4365-74. doi: 10.1021/es400386a. Epub 2013 Apr 18.
10
Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian.两种常用的群体药代动力学建模方法:非参数自适应网格法和非参数贝叶斯法。
J Pharmacokinet Pharmacodyn. 2013 Apr;40(2):189-99. doi: 10.1007/s10928-013-9302-8. Epub 2013 Feb 13.

引用本文的文献

1
Comparing computational times for simulations when using PBPK model template and stand-alone implementations of PBPK models.比较使用PBPK模型模板和PBPK模型独立实现方式进行模拟时的计算时间。
Front Toxicol. 2025 Feb 19;7:1518769. doi: 10.3389/ftox.2025.1518769. eCollection 2025.
2
A Comprehensive CYP2D6 Drug-Drug-Gene Interaction Network for Application in Precision Dosing and Drug Development.用于精准给药和药物研发的综合CYP2D6药物-药物-基因相互作用网络
Clin Pharmacol Ther. 2025 Jun;117(6):1718-1731. doi: 10.1002/cpt.3604. Epub 2025 Feb 14.
3
Static Versus Dynamic Model Predictions of Competitive Inhibitory Metabolic Drug-Drug Interactions via Cytochromes P450: One Step Forward and Two Steps Backwards.

本文引用的文献

1
An Algorithm for Nonparametric Estimation of a Multivariate Mixing Distribution with Applications to Population Pharmacokinetics.一种用于多元混合分布非参数估计的算法及其在群体药代动力学中的应用
Pharmaceutics. 2020 Dec 30;13(1):42. doi: 10.3390/pharmaceutics13010042.
2
Well-tempered MCMC simulations for population pharmacokinetic models.经过良好调整的群体药代动力学模型的 MCMC 模拟。
J Pharmacokinet Pharmacodyn. 2020 Dec;47(6):543-559. doi: 10.1007/s10928-020-09705-0. Epub 2020 Jul 31.
3
Population pharmacokinetic reanalysis of a Diazepam PBPK model: a comparison of Stan and GNU MCSim.
通过细胞色素P450对竞争性抑制性代谢药物-药物相互作用的静态与动态模型预测:前进一步,后退两步。
Clin Pharmacokinet. 2025 Jan;64(1):155-170. doi: 10.1007/s40262-024-01457-1. Epub 2024 Dec 10.
4
A Bayesian framework for virtual comparative trials and bioequivalence assessments.用于虚拟比较试验和生物等效性评估的贝叶斯框架。
Front Pharmacol. 2024 Jul 30;15:1404619. doi: 10.3389/fphar.2024.1404619. eCollection 2024.
5
Computer modeling of digestive processes in the alimentary tract and their physiological regulation mechanisms: closing the gap between digestion models and behavior.消化道消化过程及其生理调节机制的计算机建模:弥合消化模型与行为之间的差距。
Front Nutr. 2024 Mar 28;11:1339711. doi: 10.3389/fnut.2024.1339711. eCollection 2024.
6
Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare.推进精准医学:药物研发、临床药理学和个性化医疗中创新的计算机模拟方法综述。
Pharmaceutics. 2024 Feb 27;16(3):332. doi: 10.3390/pharmaceutics16030332.
7
Invited Perspective: Uneven Progress Addressing Population Variability in Human Health Risk Assessment.特邀观点:人类健康风险评估中应对人群变异性的进展参差不齐
Environ Health Perspect. 2024 Mar;132(3):31305. doi: 10.1289/EHP13461. Epub 2024 Mar 18.
8
Mapping Interindividual Variability of Toxicodynamics Using High-Throughput Transcriptomics and Primary Human Hepatocytes from Fifty Donors.利用高通量转录组学和五十名供体的原代人肝细胞绘制毒代动力学个体间变异性图谱。
Environ Health Perspect. 2024 Mar;132(3):37005. doi: 10.1289/EHP11891. Epub 2024 Mar 18.
9
Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model.采用基于生理的药代动力学模型纳入观察到的临床变异性对利特昔替尼胶囊进行虚拟生物等效性评估。
AAPS J. 2024 Jan 24;26(1):17. doi: 10.1208/s12248-024-00888-9.
人群药代动力学再分析:Diazepam PBPK 模型的 Stan 和 GNU MCSim 比较。
J Pharmacokinet Pharmacodyn. 2019 Apr;46(2):173-192. doi: 10.1007/s10928-019-09630-x. Epub 2019 Apr 4.
4
A Theoretical Physiologically-Based Pharmacokinetic Approach to Ascertain Covariates Explaining the Large Interpatient Variability in Tacrolimus Disposition.一种理论生理基于药代动力学的方法来确定解释他克莫司处置中个体间变异性较大的协变量。
CPT Pharmacometrics Syst Pharmacol. 2019 May;8(5):273-284. doi: 10.1002/psp4.12392. Epub 2019 Mar 7.
5
Can Population Modelling Principles be Used to Identify Key PBPK Parameters for Paediatric Clearance Predictions? An Innovative Application of Optimal Design Theory.能否运用群体建模原理识别儿科清除预测的关键 PBPK 参数?最优设计理论的创新性应用。
Pharm Res. 2018 Sep 14;35(11):209. doi: 10.1007/s11095-018-2487-1.
6
The Constraints, Construction, and Verification of a Strain-Specific Physiologically Based Pharmacokinetic Rat Model.一种特定应变的生理基于药代动力学大鼠模型的约束条件、构建和验证。
J Pharm Sci. 2017 Sep;106(9):2826-2838. doi: 10.1016/j.xphs.2017.05.003. Epub 2017 May 8.
7
Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance.基于生理的药代动力学(PBPK)模型的开发与应用的最新进展:从学术好奇到监管认可的转变
Curr Pharmacol Rep. 2016;2(3):161-169. doi: 10.1007/s40495-016-0059-9. Epub 2016 Apr 14.
8
Comparing the performance of FOCE and different expectation-maximization methods in handling complex population physiologically-based pharmacokinetic models.比较FOCE与不同期望最大化方法在处理复杂群体生理药代动力学模型方面的性能。
J Pharmacokinet Pharmacodyn. 2016 Aug;43(4):359-70. doi: 10.1007/s10928-016-9476-y. Epub 2016 May 23.
9
Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics.贝叶斯方法在吗啉硝唑群体药代动力学生理模型中的应用。
J Pharmacokinet Pharmacodyn. 2015 Dec;42(6):639-57. doi: 10.1007/s10928-015-9430-4. Epub 2015 Aug 1.
10
The simcyp population based simulator: architecture, implementation, and quality assurance.基于群体的Simcyp模拟器:架构、实现与质量保证。
In Silico Pharmacol. 2013 Jun 3;1:9. doi: 10.1186/2193-9616-1-9. eCollection 2013.